Portfolio Companies News
April 27, 2017Nordic Nanovector to Present at Upc...
Oslo, Norway, 27 April 2017 Nordic Nanovector ASA (OSE: NANO) announces that its Chief Executive Officer, Luigi Costa, will present an overview of the company at the following investor conferences: • Deutsche Bank Annual Healthcare Conference in Boston, MA, USA (3-4 May 2017) • Jefferies ... read more
April 27, 2017GenSight Biologics to Present GS010...
Paris, France, April 27, 2017, 7.30 CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced t... read more
April 26, 2017Onxeo: Q1 2017 financial informatio...
Revenues up 55% to €1.2 million Cash position of €21.7 million at March 31, 2017 All strategic assets are progressing according to development plans Paris, April 26, 2017 – 6.30 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology compa... read more
April 26, 2017PharmAthene and Altimmune Announce ...
April 26, 2017 – As previously announced, PharmAthene, Inc. (NYSE MKT: PIP) and Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious diseases, have signed a definitive agreement for the merger of PharmAthene and Altimmune in an all-stock transaction. Today, the compani... read more
April 26, 2017GenSight Biologics reports its cash...
Paris, France, April 26, 2017, 7.30 CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today rep... read more
February 06, 2017Q4 2016 General Market Overview
- 106 Since the start in 1996, HealthCap funds have invested in 106 portfolio companies.
- 39 39 of the portfolio companies have been taken public on nine different markets.
- 22 22 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 6 companies with a valuation of USD 1 billion or more and 34 companies with a valuation of SEK 1 billion or more.